Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1803176-05-7] Oleclumab
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P99039 |
| Brand: | MCE |
| CAS: | 1803176-05-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Oleclumab] |
For research use only. We do not sell to patients.
Summary
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04261075 | MedImmune LLC |
Advanced Solid Tumors
|
March 3, 2020 | Phase 1 |
| NCT03616886 | Jules Bordet Institute|AstraZeneca |
Triple Negative Breast Cancer
|
December 28, 2018 | Phase 1|Phase 2 |
| NCT03819465 | AstraZeneca |
Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
December 27, 2018 | Phase 1 |
| NCT03742102 | AstraZeneca |
Triple Negative Breast Neoplasms
|
December 21, 2018 | Phase 1|Phase 2 |
| NCT04668300 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Angiosarcoma|Metastatic Dedifferentiated Liposarcoma|Metastatic Osteosarcoma|Recurrent Angiosarcoma|Recurrent Dedifferentiated Liposarcoma|Recurrent Osteosarcoma|Refractory Dedifferentiated Liposarcoma|Refractory Osteosarcoma
|
November 26, 2020 | Phase 2 |
| NCT03875573 | Jules Bordet Institute|Institut Curie|AstraZeneca |
Luminal B
|
November 6, 2019 | Phase 2 |
| NCT04262375 | University Health Network, Toronto|AstraZeneca |
Non Small Cell Lung Cancer|Renal Cell Carcinoma
|
January 2021 | Phase 2 |
| NCT04940286 | M.D. Anderson Cancer Center |
Borderline Resectable Pancreatic Adenocarcinoma|Resectable Pancreatic Adenocarcinoma|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8
|
September 28, 2021 | Phase 2 |
| NCT02503774 | MedImmune LLC |
Solid Tumors
|
July 24, 2015 | Phase 1 |
| NCT03833440 | Assistance Publique Hopitaux De Marseille |
Non-small Cell Lung Cancer
|
October 8, 2019 | Phase 2 |
| NCT03381274 | MedImmune LLC |
Carcinoma, Non-Small-Cell Lung
|
May 8, 2018 | Phase 1|Phase 2 |
| NCT03736473 | AstraZeneca |
Advanced Solid Malignancies
|
November 7, 2018 | Phase 1 |
| NCT05061550 | AstraZeneca|Parexel |
Non-small Cell Lung Cancer
|
April 14, 2022 | Phase 2 |
| NCT04262388 | University Health Network, Toronto|AstraZeneca |
Pancreatic Ductal Adenocarcinoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck
|
January 2021 | Phase 2 |
| NCT05221840 | AstraZeneca |
Non-Small Cell Lung Cancer
|
February 7, 2022 | Phase 3 |
| NCT04145193 | MedImmune LLC |
Microsatellite-stable Colorectal Cancer
|
October 1, 2020 | Phase 2 |
| NCT03794544 | MedImmune LLC |
Resectable|Early-stage|NSCLC
|
March 8, 2019 | Phase 2 |
| NCT04089553 | AstraZeneca |
Prostate Cancer|Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
August 29, 2019 | Phase 2 |
| NCT03611556 | MedImmune LLC |
Carcinoma|Metastatic Pancreatic Adenocarcinoma
|
June 21, 2018 | Phase 1|Phase 2 |
| NCT03822351 | MedImmune LLC |
Stage III Non-small Cell Lung Cancer|Unresectable
|
December 19, 2018 | Phase 2 |
| NCT02740985 | AstraZeneca |
Advanced Solid Malignancies|Non-Small Cell Lung Cancer (NSCLC)|Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)|Colorectal Carcinoma (CRC)
|
June 17, 2016 | Phase 1 |
| NCT03773666 | Dana-Farber Cancer Institute|AstraZeneca |
Muscle Invasive Bladder Cancer
|
February 20, 2019 | Phase 1 |
| NCT03334617 | AstraZeneca |
Non-Small Cell Lung Cancer
|
December 18, 2017 | Phase 2 |
Appearance
Liquid
Shipping
Shipping with dry ice.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.